FDA
-
-
-
-
-
-
-
X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
-
-
-
-
-
-
-
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference
-
-
-
-
-
-
-
Sitryx appoints Adam Mostafa as Chief Financial Officer
-
-
-
-
-
-
-
X4 Pharmaceuticals (XFOR) Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome
-
-
-
-
-
-
-
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
-
-
-
-
-
-
-
X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome
-
-
-
-
-
-
-
X4 Pharmaceuticals Announces Industry Veteran Dr. Christophe Arbet-Engels to Join as Chief Medical Officer
-
329,910 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

